-+ 0.00%
-+ 0.00%
-+ 0.00%

HC Wainwright & Co. Downgrades Sutro Biopharma to Neutral, Lowers Price Target to $2

Benzinga·03/17/2025 12:53:38
Listen to the news
HC Wainwright & Co. analyst Andrew Fein downgrades Sutro Biopharma (NASDAQ:STRO) from Buy to Neutral and lowers the price target from $12 to $2.